Breaking Up With Beta-Blockers After a Heart Attack

Key Takeaway: A pooled analysis combining data from over 6,200 stable heart attack patients from two randomized controlled trials has revealed that discontinuing beta-blocker therapy is as safe as continuing it regarding rates of death, heart attack, stroke, and cardiovascular hospitalization. This finding represents the strongest evidence to date that long-term beta-blocker therapy can be safely stopped in patients with preserved heart function and no heart failure.

The Pill That Became a Lifelong Companion

For millions who have had a heart attack, the small daily beta-blocker pill has been a habit as routine as brushing their teeth—a medication started in the hospital and never questioned again. For decades, the directive was simple: take this drug, keep taking it, likely for life. The original rationale was sound, rooted in 1980s trials that showed dramatic reductions in mortality in the months following a heart attack^[2]. But medicine in the 1980s was a world away from today’s. Patients then were not routinely receiving emergency stenting, high-potency statins, and dual antiplatelet therapy—the pillars of modern cardiac care. Years later, the question of whether beta-blockers still belonged on the medication list for a stable patient whose heart was pumping normally remained a largely unanswered question. Until now.

What Did the Researchers Do?

An international team of investigators pooled individual patient data from two groundbreaking randomized controlled trials—ABYSS and SMART-DECISION—involving a total of 6,238 patients who were stable following a myocardial infarction. These patients were not in the acute phase. A median of 3.6 years had passed since their heart attacks, their left ventricular ejection fraction (LVEF)—the percentage of blood the heart pumps with each beat—was 40% or higher, and none had active heart failure or another compelling reason to remain on a beta-blocker. Participants were randomly assigned to either stop or continue their beta-blockers and then followed for the most critical clinical events: death, another heart attack, stroke, or hospitalization for cardiovascular causes.

What Were the Findings?

The results were definitive. Discontinuing beta-blocker therapy was “non-inferior” to continuing therapy for the primary composite endpoint of death, myocardial infarction, stroke, or cardiovascular hospitalization. The hazard ratio was 1.09 (95% confidence interval 0.97–1.24; p = 0.016 for non-inferiority)^[1]. In practical terms, this meant that stopping the drug did not lead to a meaningful increase in any of these serious outcomes. The findings were even more reassuring for the secondary endpoint of harder outcomes—death, heart attack, or hospitalization for heart failure—where the hazard ratio was 1.01 (95% CI 0.83–1.23; p = 0.0006 for non-inferiority). A hazard ratio hovering around 1.01 is about as close to perfect equivalence as one can get in clinical medicine. Crucially, these findings held true regardless of where a patient’s ejection fraction fell within the eligible range, suggesting the safety signal is robust across the spectrum of preserved heart function.

Why Were Beta-Blockers Prescribed in the First Place?

To grasp the significance, a brief detour into pharmacology is necessary. Beta-blockers like metoprolol, atenolol, and bisoprolol work by blocking the effects of adrenaline (epinephrine) and noradrenaline on beta-1 adrenergic receptors in the heart^[3]. This slows the heart rate, lowers blood pressure, and reduces the heart’s demand for oxygen. In the vulnerable weeks following a heart attack, when the damaged myocardium is susceptible to dangerous arrhythmias and further ischemia, these effects are truly life-saving. The landmark trials that cemented the role of beta-blockers in post-MI care—notably the Norwegian Timolol Study and the Beta-Blocker Heart Attack Trial (BHAT)—showed clear mortality benefits in the pre-reperfusion era^[2][4]. But these studies were conducted before percutaneous coronary intervention became standard, before dual antiplatelet therapy, high-intensity statins, and the routine use of ACE inhibitors. The landscape of secondary prevention has been completely transformed. The incremental benefit of a beta-blocker in a patient years after their acute event, with a well-functioning heart and already on all these modern therapies, remained an open question—one that guideline committees have acknowledged with increasingly ambiguous language^[5].

Meanwhile, the costs of indefinite beta-blocker use are not trivial. Fatigue, exercise intolerance, weight gain, sexual dysfunction, depressive symptoms, and sleep disturbances are common side effects that can diminish quality of life^[3]. These trade-offs become difficult to justify for a drug providing marginal benefit in an already optimally treated, stable patient.

Notable Limitations

No single analysis, however large, closes the book on a topic. The primary composite endpoint included cardiovascular hospitalization, a ‘softer’ outcome that can be influenced by clinical decision-making as much as by biology. The authors themselves acknowledge this. It is deeply reassuring, however, that the secondary endpoint, which was restricted to the harder events of death, MI, and heart failure hospitalization, showed even stronger non-inferiority. Additionally, while 6,238 patients is a substantial cohort, longer-term follow-up data would be valuable to confirm that no late divergence in outcomes emerges. Patients with a reduced ejection fraction (below 40%) or active heart failure were excluded, and for these populations, beta-blockers remain a cornerstone of therapy, supported by robust evidence^[6].

What These Results Mean for Tomorrow’s Patients

This pooled analysis is practice-changing for a well-defined group: stable heart attack survivors, years out from their event, with preserved heart function and no heart failure. For these patients, the evidence now strongly suggests that the reflexive continuation of beta-blocker therapy is not supported by the data. Physicians can confidently approach the conversation about discontinuation, armed with the knowledge that hard clinical endpoints like death, recurrent heart attack, and heart failure are not worsened by stopping therapy. This does not mean abandoning a class of drugs that has saved countless lives in the acute setting. It is to recognize that the biology of a heart three or four years after a well-treated infarct is fundamentally different from that of a heart in the first weeks post-event. The era of one-size-fits-all, lifelong beta-blocker therapy for every post-MI patient appears to be closing, giving way to a more nuanced, individualized approach that weighs ongoing benefit against the real burden of unnecessary medication.

Scientific Sources

1. Silvain J, et al. Discontinuation of β-blockers in stable patients with previous myocardial infarction, preserved left ventricular ejection fraction, and no heart failure: a pooled analysis of individual patient data. Lancet (London, England). 2026. PubMed: https://pubmed.ncbi.nlm.nih.gov/42669300/
2. Norwegian Multicenter Study Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med. 1981. DOI: 10.1056/NEJM198104023041401
3. Frishman WH. Beta-adrenergic blockers: adverse effects and drug interactions. Hypertension. 1988. DOI: 10.1161/01.hyp.11.3_pt_2.ii21
4. Beta-Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction. JAMA. 1983. DOI: 10.1001/jama.1983.03340200048027
5. Byrne RA, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023. DOI: 10.1093/eurheartj/ehad191
6. Packer M, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001. DOI: 10.1056/NEJM200105313442201